|Bid||110.250 x 1100|
|Ask||110.410 x 1300|
|Day's Range||110.17 - 111.56|
|52 Week Range||104.28 - 134.55|
|Beta (3Y Monthly)||1.45|
|PE Ratio (TTM)||12.90|
|Earnings Date||Jan 28, 2019 - Feb 1, 2019|
|Forward Dividend & Yield||0.96 (0.85%)|
|1y Target Est||134.84|
WARSAW, Ind. , Dec. 12, 2018 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the ...
NEW YORK, Dec. 10, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article, we look at what those funds think of Zimmer Biomet Holdings Inc (NYSE:ZBH) based on […]
In order to tackle several near-term concerns, Zimmer Biomet (ZBH) of late begins to review its 2018 operating plan to clearly define its go-forward strategies in a number of thrust areas.
European weapons makers to consolidate, the German government's armaments director said on Wednesday, and warned that failing to reduce the continent's fragmented defence industry could make Europe obsolete. Arms makers need to move beyond mere cooperation agreements and deepen ties, Benedikt Zimmer told hundreds of industry executives and military and government officials at the Berlin Security Conference, and said the drive was supported by the top levels of the German government.
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Comcast, ConocoPhillips, Delta Air Lines, ServiceNow and Zimmer Biomet
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...
Zimmer (ZBH) delivered earnings and revenue surprises of 1.87% and 0.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Warsaw, Indiana-based company said it had net income of 79 cents. Earnings, adjusted for one-time gains and costs, were $1.63 per share. The results exceeded Wall Street expectations. ...
- Net sales of $1.837 billion for the third quarter represent an increase of 1.3% over the prior year period, and an increase of 2.3% on a constant currency basis - Diluted EPS for the third quarter were ...
Short interest is extremely low for ZBH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZBH. The $3.07 billion in inflows that ETFs holding ZBH received over the last one-month is a decline from earlier in the period and among the weakest of the past year.
The Shuman Law Firm announces that it is investigating potential shareholder claims against certain officers and directors of Zimmer Biomet Holdings, Inc. (“ZBH” or the “Company”) (Nasdaq: ZBH). ZBH designs, manufactures, and markets musculoskeletal healthcare products. The lawsuit alleges that these defendants made materially false statements relating to the financial performance of ZBH during the summer and fall of 2016 by concealing compliance issues at a key factory.
Focusing on areas like quality correction, supply recovery and product introductions, Zimmer Biomet (ZBH) is expected to see robust top-line numbers at S.E.T. arm in Q3.
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Barclays initiates coverage on medical technology names with a positive view. Top picks include Abbott Labs, Boston Scientific, Stryker, and Medtronic.